To: All persons and/or entities who purchased common stock in Stemline Therapeutics, Inc. (NASDAQ: STML). during the period from January 19, 2017 through February 1, 2017, and were damaged thereby; a settlement has been announced in the securities litigation known as In re Stemline Therapeutics, Inc. Securities Litigation, Master File No. 1:17-CV-00832-PAC, United States District Court for the Southern District of New York. For additional information about this settlement, please see the Notice and Proof of Claim (links provided below):
- Notice of Pendency and Proposed Settlement of Class Action and Settlement Fairness Hearing;
- Proof of Claim and Release.
Claim submission deadline is Wednesday, October 23, 2019.
If you have any questions about the settlement, please contact the Claims Administrator. Their contact information can be found in the attached Notice.